ReviewJACC. Basic to translational science2026
Endothelial Cells at the Crossroad of Atherosclerosis and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Unifying Target for Dual Treatment.
Review in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) are 2 highly prevalent conditions that frequently coexist and amplify each other's clinical burden. MASLD not only increases cardiovascular disease incidence but also promotes atherosclerosis independently of traditional risk factors, including obesity, diabetes, and dyslipidemia. Despite this strong clinical association, the biological mechanisms linking these diseases remain incompletely understood. Emerging evidence identifies endothelial dysfunction as a unifying pathogenic axis underlying their crosstalk. In atherosclerosis, vascular endothelial dysfunction facilitates lipoprotein retention, leukocyte recruitment, and plaque formation. Similarly, in MASLD, liver sinusoidal endothelial cells lose their capacity to regulate lipid trafficking, immune tolerance, and hepatic homeostasis, thereby promoting steatosis, inflammation, and fibrosis. This review highlights endothelial dysfunction as a common denominator in both diseases, emphasizing shared molecular mechanisms such as impaired nitric oxide production, oxidative stress, and cytokine-driven inflammation. We further discuss how metabolic disturbances including insulin resistance and dyslipidemia exacerbate endothelial activation, lipid accumulation, and immune cell responses across vascular and hepatic beds. By examining the interplay between MASLD and atherosclerosis at the endothelial level, we propose endothelial cells as a promising therapeutic target for both conditions. Emerging strategies, such as targeted cell therapies and nanomedicine, offer the potential to simultaneously address endothelial dysfunction in the liver and vasculature. Future research should prioritize therapies that address this shared endothelial axis, with the potential to reduce the morbidity and mortality associated with these interconnected diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.